医学
临床试验
从长凳到床边
神经病理性疼痛
药理学
神经痛
药物发现
翻译(生物学)
药代动力学
生物信息学
内科学
信使核糖核酸
化学
医学物理学
基因
生物
生物化学
作者
Andrew J. Shepherd,Andrew S.C. Rice,Maree T. Smith
标识
DOI:10.1016/j.coph.2023.102415
摘要
Translating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety profile and good pharmacokinetics. Herein, we provide an overview of the discovery, preclinical and clinical development of EMA401, for the alleviation of peripheral neuropathic pain.
科研通智能强力驱动
Strongly Powered by AbleSci AI